JP2019513412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513412A5 JP2019513412A5 JP2018568171A JP2018568171A JP2019513412A5 JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5 JP 2018568171 A JP2018568171 A JP 2018568171A JP 2018568171 A JP2018568171 A JP 2018568171A JP 2019513412 A5 JP2019513412 A5 JP 2019513412A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- nanoparticles
- paramagnetic
- expanded
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309234P | 2016-03-16 | 2016-03-16 | |
| US62/309,234 | 2016-03-16 | ||
| PCT/US2017/022663 WO2017161092A1 (en) | 2016-03-16 | 2017-03-16 | Production of antigen-specific t-cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513412A JP2019513412A (ja) | 2019-05-30 |
| JP2019513412A5 true JP2019513412A5 (cg-RX-API-DMAC7.html) | 2020-04-23 |
| JP7016098B2 JP7016098B2 (ja) | 2022-02-21 |
Family
ID=59850933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568171A Active JP7016098B2 (ja) | 2016-03-16 | 2017-03-16 | 抗原特異的t細胞の生成 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200291381A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3445399A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7016098B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102470979B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475620A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017233035B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3017615A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261710A (cg-RX-API-DMAC7.html) |
| RU (2) | RU2021107053A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10202008210XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017161092A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7054397B2 (ja) * | 2016-06-27 | 2022-04-13 | ジュノー セラピューティクス インコーポレイテッド | Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用 |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| CN111787930B (zh) * | 2017-10-06 | 2024-12-20 | 芝加哥大学 | 针对癌症特异性抗原对t淋巴细胞的筛选 |
| AU2019291071B2 (en) * | 2018-06-20 | 2026-01-08 | Danmarks Tekniske Universitet | Scaffolds with stabilized MHC molecules for immune-cell manipulation |
| AU2019345052B2 (en) * | 2018-09-19 | 2025-09-04 | FUJIFILM Cellular Dynamics, Inc. | Protein L for activation and expansion of chimeric antigen receptor-modified immune cells |
| CN109136276A (zh) * | 2018-09-30 | 2019-01-04 | 北京鼎成肽源生物技术有限公司 | 一种rfft2细胞的构建方法 |
| JP7863702B2 (ja) | 2018-11-08 | 2026-05-22 | セルキュア インコーポレイテッド | 表現型特性が向上したt細胞組成物 |
| WO2021173847A1 (en) * | 2020-02-27 | 2021-09-02 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Cobra1/nelf-b as a booster for efficacy of cd8+ t cell-based therapy |
| EP4172352A4 (en) * | 2020-06-26 | 2024-07-03 | The Johns Hopkins University | Adaptive nanoparticle platforms for high throughput expansion and detection of antigen-specific t cells |
| WO2022125901A1 (en) * | 2020-12-11 | 2022-06-16 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| JP2024510244A (ja) * | 2021-03-17 | 2024-03-06 | ミルテニー バイオテック ベー.フェー. ウント コー. カー・ゲー | 抗原特異的活性化及びcar t細胞の増殖のための人工標的 |
| WO2023060217A1 (en) * | 2021-10-08 | 2023-04-13 | Baylor College Of Medicine | Transgenic t cell receptors targeting neoantigens for diagnosis, prevention, and/or treatment of hematological cancers |
| WO2023144275A1 (en) * | 2022-01-28 | 2023-08-03 | Katholieke Universiteit Leuven | Actuation of organoids by magnetic nanoparticles |
| DE102022132082B4 (de) * | 2022-12-02 | 2024-08-08 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung. |
| WO2026035444A1 (en) * | 2024-07-24 | 2026-02-12 | Cellkure, Inc. | Methods for identifying functional neoantigens and their use in cancer immunotherapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
| JPH11507843A (ja) | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| US6140113A (en) | 1996-03-28 | 2000-10-31 | The Johns Hopkins University | Polynucleotides encoding molecular complexes which modify immune responses |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| CA2359636A1 (en) | 1999-01-22 | 2000-07-27 | Andrew W. Taylor | Activation of regulatory t cells by alpha-melanocyte stimulating hormone |
| US6746670B2 (en) | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| RU2311920C2 (ru) * | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| US6670146B2 (en) | 2000-10-04 | 2003-12-30 | Schering Corporation | Regulatory T cells; methods |
| US20030049696A1 (en) | 2001-06-07 | 2003-03-13 | Norment Anne M. | Regulatory T cells and uses thereof |
| JP2003102471A (ja) | 2001-10-01 | 2003-04-08 | Kirin Brewery Co Ltd | 調節性t細胞の分化誘導・増殖促進方法 |
| WO2004104185A1 (en) * | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
| AT503861B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| CN102168066A (zh) * | 2011-01-31 | 2011-08-31 | 浙江大学 | 体外诱导乙型肝炎病毒特异性细胞毒性t淋巴细胞的方法 |
| US10758487B2 (en) | 2011-12-09 | 2020-09-01 | The Johns Hopkins University | Artificial antigen presenting cells having a defined and dynamic shape |
| KR20210149195A (ko) * | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 t 세포의 투여 적합성을 평가하는 방법 |
| MX376790B (es) * | 2013-03-14 | 2025-03-07 | Univ Johns Hopkins | Células presentadoras de antígeno artificiales de nanoescala. |
| AU2014302784B2 (en) | 2013-06-24 | 2020-01-23 | Neximmune | Compositions and methods for immunotherapy |
| US11807675B2 (en) * | 2013-10-03 | 2023-11-07 | The University Of Maryland, Baltimore | Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells |
| US10066265B2 (en) * | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
| KR20160016725A (ko) * | 2014-08-05 | 2016-02-15 | 주식회사 유영제약 | 암 세포에 과발현되는 IL13Rα2에 특이적으로 결합하는 키메라 항원 수용체로 변형된 T 세포 |
| JP6743022B2 (ja) | 2014-12-24 | 2020-08-19 | ネクシミューン インコーポレイテッド | 免疫療法のためのナノ粒子組成物及び方法 |
-
2017
- 2017-03-16 WO PCT/US2017/022663 patent/WO2017161092A1/en not_active Ceased
- 2017-03-16 KR KR1020187029819A patent/KR102470979B1/ko active Active
- 2017-03-16 SG SG10202008210XA patent/SG10202008210XA/en unknown
- 2017-03-16 CA CA3017615A patent/CA3017615A1/en active Pending
- 2017-03-16 JP JP2018568171A patent/JP7016098B2/ja active Active
- 2017-03-16 SG SG11201807940XA patent/SG11201807940XA/en unknown
- 2017-03-16 RU RU2021107053A patent/RU2021107053A/ru unknown
- 2017-03-16 CN CN201780030022.4A patent/CN109475620A/zh active Pending
- 2017-03-16 AU AU2017233035A patent/AU2017233035B2/en active Active
- 2017-03-16 RU RU2018136203A patent/RU2745319C2/ru active
- 2017-03-16 EP EP17767506.3A patent/EP3445399A4/en active Pending
- 2017-03-17 US US16/084,121 patent/US20200291381A1/en not_active Abandoned
-
2018
- 2018-09-12 IL IL261710A patent/IL261710A/en unknown
-
2023
- 2023-02-21 US US18/111,975 patent/US20230332131A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022287548B2 (en) | T Cells For Expression Of Chimeric Antigen Receptors And Other Receptors | |
| Huff et al. | The evolving role of CD8+ CD28− immunosenescent T cells in cancer immunology | |
| US20250002850A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
| Parent et al. | Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection | |
| Somanchi et al. | Expansion, purification, and functional assessment of human peripheral blood NK cells | |
| Lässer et al. | Isolation and characterization of RNA-containing exosomes | |
| EP3188740B1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
| JP2016509839A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509840A5 (cg-RX-API-DMAC7.html) | ||
| Voskamp et al. | Immunotherapy in medulloblastoma: current state of research, challenges, and future perspectives | |
| JP2016539929A5 (cg-RX-API-DMAC7.html) | ||
| Moreira-Teixeira et al. | Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells | |
| JP2013177430A5 (cg-RX-API-DMAC7.html) | ||
| WO2018175408A8 (en) | METHODS AND COMPOSITIONS FOR MODULATION OF IMMUNE CELLS | |
| Dohnal et al. | Comparative evaluation of techniques for the manufacturing of dendritic cell‐based cancer vaccines | |
| JP2013523841A5 (cg-RX-API-DMAC7.html) | ||
| RU2018136203A (ru) | Получение антигенспецифических t-клеток | |
| JP2012521769A5 (cg-RX-API-DMAC7.html) | ||
| Watts et al. | Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS®(v2· 1) and Isolex® 300i (v2· 5) clinical scale devices | |
| Stockinger et al. | CD4 T-cell memory | |
| Lesterhuis et al. | PD-L2 is predominantly expressed by Th2 cells | |
| van Bruggen et al. | Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma | |
| Esmaeili et al. | Spiky gold nanoparticles, a nanoscale approach to enhanced ex vivo T-cell activation | |
| Edri et al. | Nicotinamide-expanded allogeneic natural killer cells with CD38 deletion, expressing an enhanced CD38 chimeric antigen receptor, target multiple myeloma cells | |
| WO2005094353A2 (en) | Methods for production of regulatory t cells and uses thereof |